Increasing Adoption of Facial Rejuvenation and Approval and Launch of New Products to Augment Growth of Facial Rejuvenation Market

 

Facial Rejuvenation Market

Facial rejuvenation is basically a cosmetic procedure, which aims to bring about a more youthful look to the face. Facial rejuvenation may be achieved through both non-invasive and invasive methods. Non-invasive procedures can range from mild to highly invasive. These procedures have also evolved significantly over the past decade or so. More recently, non-invasive procedures have become popular options for achieving facial rejuvenation.

Market Dynamics

Approval and launch of new products is expected to propel growth of the facial rejuvenation market. For instance, in August 2020, Cutera, Inc. launched its new Fraxis PRO progressive dermal remodeling technology. Moreover, increasing adoption of facial rejuvenation is also expected to aid in growth of the market. For instance, according to International Society of Aesthetic Plastic Surgery, photo rejuvenation was one of the top five nonsurgical procedures for women and accounted for 347,305 procedures in 2019.

Increasing expenditure on personal care products is expected to offer lucrative growth opportunities in facial rejuvenation market. For instance, according to the U.S. Bureau of Labor Statistics, average annual expenditure on personal care products in the U.S. increased from US$ 707 in 2016 to US$ 768 in 2018. Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.

Among regions, North America is expected to witness significant growth in the global facial rejuvenation market, owing to increasing adoption of facial rejuvenation in the region. For instance, in August 2019, A-to-Zen Regenerative Medicine in Bellevue, Washington, announced expansion of leading menu of skin rejuvenation treatments with state-of-the-art platelet-rich plasma (PRP) Facials and PRP Facelifts for all-natural, age-defying complexion benefits.

Competitive Analysis 

Major players operating in the global facial rejuvenation market include, Merz Pharma GmbH & Co. KGaA, Anika Therapeutics, Inc., Lumenis, Galderma, Allergan (Actavis), Contura Ltd., Fibrocell Science, Inc., and Revance Therapeutics.

The global facial rejuvenation market is witnessing divesture strategies. For instance, in April 2019, Merz Pharma GmbH & Co. KGaA and Laboratoire HRA Pharma SAS, a consumer healthcare company, signed an asset purchase agreement, pursuant to which HRA Pharma will acquire the global rights to the Mederma brand, which includes products across the scar care, stretch marks and skin care categories.

Location: United States

Comments

Post a Comment

Popular posts from this blog

The Emergence of COVID-19 to Augment Growth of the Outsourced Drug Discovery Market

Image
  With billions of dollars in research and development costs, pharmaceutical companies around the world are always looking for new ways to address their production processes in a cost-effective manner. One way to achieve this is through outsourcing drug discovery and development services. This type of service refers to the collaboration between small and large biotech and biotechnology companies to conduct research and development activities aimed at finding better solutions to the company's core chemical concerns. Outsourcing of these drug discovery services has enabled established pharmaceutical and biotechnology companies to focus on the development of new products that can bring about significant therapeutic change and provide tangible advantages to the company's shareholders. Contract research organizations manage almost all aspects of drug discovery. Market Dynamics I ncreasing demand for outsourcing analytical testing and clinical trial services, growing R&D ex...
Read more

Otoscope Market Is Gaining Major Traction with Industry Leader Otonexus Medical Technologies Introducing Ultrasound Sensor, Which Aids Middle-Ear Infection Diagnosis

Image
  An otoscope or auricular ear picker is a simple health care tool that is used to inspect the outer ear. Many health care professionals utilize otoscopes to examine ear infections during routine check-ups and to also screen for serious ear disorders. An otoscope possibly provides a more detailed view of the external ear canal and/or ear drum or eardrum. Otoscope or also referred to as auriscope is mainly used to look into eyes. The demand for these medical devices has been on a rise in the recent past. This is typically due to the fact that there is a high burden of ENT-related diseases across the globe. As per the World Health Organization (WHO), by 2050, around 2.5 billion people are estimated to have some degree of hearing loss worldwide. Similarly, there is a heavy burden of sinusitis cases. As per the Sinusitis & Allergy Wellness Center, around 30 million adults in the U.S. are impacted with sinusitis annually. Such a high prevalence of ENT disorders has accelerated the d...
Read more

The Number of Cancer Survivors Is Projected To Increase to 22.2 Million By 2030 Fostering Oncology Drug Pipeline Analysis Market

Image
  North America is estimated to dominate the global oncology drug pipeline analysis market in the near future and this is attributed to the high prevalence of cancer and increasing launch of various novel drugs with improved efficacy. According to the National Cancer Institute, as of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030. The oncology field is experiencing significant growth and this is attributed to the increasing development of various novel therapies for the treatment of cancer. For instance, in February 2021, Rhizen Pharmaceuticals AG, a clinical-stage, oncology-focused biopharma company, with a 50% stake owned by Alembic Pharmaceuticals and the rest by its Indian CEO Swaroop Vakkalanka, has announced that its the novel, next-generation PI3K-delta inhibitor Umbralisib (Ukoniq) has secured U.S. FDA accelerated approval for the treatment of blood c...
Read more